Back to search
FDAFDA · Food and drugs·Recall number D-1448-2019

MethylPREDNISolone Tablets, USP, 4 mg, 100 tablets, Rx only, Manufactured by: Cadila Healthcare Ltd Ahmedabad, India NDC 68382-916-01

Published June 26, 2019 · Recall initiated: May 6, 2019

Summary

FDA records drug Class II recall D-1448-2019, published June 26, 2019 and initiated May 6, 2019. Recalling firm: Zydus Pharmaceuticals USA Inc; Status: Terminated; Reported quantity: 34521 100-count bottles; Lot: Lots: M800144, M800145, EXP, Feb-20; M808193, EXP Jun-20; M811096, EXPJul-20. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

What to do

Voluntary: Firm initiated · Letter

Get an email if METHYLPREDNISOLONE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
METHYLPREDNISOLONE
Manufacturer
Zydus Pharmaceuticals USA Inc
Distributor
Nationwide in the USA
Lot
Lots: M800144, M800145, EXP, Feb-20; M808193, EXP Jun-20; M811096, EXPJul-20
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was MethylPREDNISolone Tablets, USP, 4 mg, 100 tablets, Rx only, Manufactured by: Cadila Healthcare Ltd Ahmedabad, India NDC 68382-916-01 recalled?

Yes. FDA published recall D-1448-2019 on June 26, 2019. Reported hazard: CGMP Deviations: Cross Contamination with other products due to CGMP cleaning failure.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: METHYLPREDNISOLONE.